Loading...

NanoCarrier

DB:3NQ
Snowflake Description

Adequate balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
3NQ
DB
¥21B
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceutical products using micellar nanoparticle technology primarily for the treatment of cancer in Japan. The last earnings update was 67 days ago. More info.


Add to Portfolio Compare Print
  • NanoCarrier has significant price volatility in the past 3 months.
3NQ Share Price and Events
7 Day Returns
0.8%
DB:3NQ
-2.4%
DE Biotechs
1.8%
DE Market
1 Year Returns
-35.8%
DB:3NQ
-10.2%
DE Biotechs
-6%
DE Market
3NQ Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
NanoCarrier (3NQ) 0.8% -8.4% 8.9% -35.8% -76.8% -60.3%
DE Biotechs -2.4% 3.2% -7.7% -10.2% 51.2% 10.1%
DE Market 1.8% 4.6% 7.4% -6% 10.1% 15.3%
1 Year Return vs Industry and Market
  • 3NQ underperformed the Biotechs industry which returned -10.2% over the past year.
  • 3NQ underperformed the Market in Germany which returned -6% over the past year.
Price Volatility
3NQ
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for NanoCarrier's competitors could be found in our database.

Value

 Is NanoCarrier undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of NanoCarrier to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for NanoCarrier.

DB:3NQ Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8.4%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:3NQ
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 30.86%) (11.68%))
1.378
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.38
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.378 * 5.96%)
8.44%

Discounted Cash Flow Calculation for DB:3NQ using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for NanoCarrier is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:3NQ DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (JPY, Millions) Source Present Value
Discounted (@ 8.44%)
2019 -1,770.00 Analyst x2 -1,632.20
2020 -1,231.50 Analyst x2 -1,047.21
2021 -584.00 Analyst x2 -457.95
2022 -458.00 Analyst x2 -331.18
2023 398.00 Analyst x2 265.39
2024 1,469.00 Analyst x2 903.28
2025 2,461.90 Est @ 67.59% 1,395.96
2026 3,628.39 Est @ 47.38% 1,897.22
2027 4,834.30 Est @ 33.24% 2,330.97
2028 5,962.30 Est @ 23.33% 2,651.05
Present value of next 10 years cash flows ¥5,975.33
DB:3NQ DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= ¥5,962.30 × (1 + 0.23%) ÷ (8.44% – 0.23%)
¥72,747.98
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= ¥72,747.98 ÷ (1 + 8.44%)10
¥32,346.33
DB:3NQ Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= ¥5,975.33 + ¥32,346.33
¥38,321.66
Equity Value per Share
(JPY)
= Total value / Shares Outstanding
= ¥38,321.66 / 49.40
¥775.7
DB:3NQ Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:3NQ represents 0.00766x of TSE:4571
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.00766x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (JPY) x Listing Adjustment Factor
= ¥ 775.70 x 0.00766
€5.95
Value per share (EUR) From above. €5.95
Current discount Discount to share price of €3.29
= -1 x (€3.29 - €5.95) / €5.95
44.7%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price NanoCarrier is available for.
Intrinsic value
45%
Share price is €3.29 vs Future cash flow value of €5.95
Current Discount Checks
For NanoCarrier to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • NanoCarrier's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • NanoCarrier's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for NanoCarrier's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are NanoCarrier's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:3NQ PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in JPY ¥-49.64
TSE:4571 Share Price ** TSE (2019-04-18) in JPY ¥429
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.44x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.59x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of NanoCarrier.

DB:3NQ PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSE:4571 Share Price ÷ EPS (both in JPY)

= 429 ÷ -49.64

-8.64x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NanoCarrier is loss making, we can't compare its value to the Europe Biotechs industry average.
  • NanoCarrier is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does NanoCarrier's expected growth come at a high price?
Raw Data
DB:3NQ PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -8.64x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
17.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for NanoCarrier, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on NanoCarrier's assets?
Raw Data
DB:3NQ PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in JPY ¥103.99
TSE:4571 Share Price * TSE (2019-04-18) in JPY ¥429
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.84x
DB:3NQ PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSE:4571 Share Price ÷ Book Value per Share (both in JPY)

= 429 ÷ 103.99

4.13x

* Primary Listing of NanoCarrier.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • NanoCarrier is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess NanoCarrier's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. NanoCarrier has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is NanoCarrier expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
17.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is NanoCarrier expected to grow at an attractive rate?
  • NanoCarrier's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • NanoCarrier's earnings growth is expected to exceed the Germany market average.
  • NanoCarrier's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:3NQ Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:3NQ Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 17.7%
DB:3NQ Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 18.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:3NQ Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in JPY Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:3NQ Future Estimates Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-03-31 3,042 -65 -23 1
2023-03-31 1,301 -1,599 -1,606 1
2022-03-31 1,160 -1,568 -1,664 1
2021-03-31 1,780 -517 -957 2
2020-03-31 2,720 -714 11 2
2019-03-31 460 -2,366 -2,222 2
DB:3NQ Past Financials Data
Date (Data in JPY Millions) Revenue Cash Flow Net Income *
2018-12-31 456 -2,245
2018-09-30 406 -4,218 -4,276
2018-06-30 266 -4,793
2018-03-31 259 -4,927 -5,416
2017-12-31 213 -5,551
2017-09-30 205 -3,013 -2,954
2017-06-30 215 -2,888
2017-03-31 218 -2,525 -2,676
2016-12-31 298 -2,920
2016-09-30 313 -2,482 -3,402
2016-06-30 269 -3,278
2016-03-31 243 -1,971 -2,537

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • NanoCarrier's earnings are expected to grow by 17.7% yearly, however this is not considered high growth (20% yearly).
  • NanoCarrier's revenue is expected to grow by 18.3% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:3NQ Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from NanoCarrier Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:3NQ Future Estimates Data
Date (Data in JPY Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-03-31 -0.50 -0.50 -0.50 1.00
2023-03-31 -34.60 -34.60 -34.60 1.00
2022-03-31 -35.90 -35.90 -35.90 1.00
2021-03-31 -20.62 1.30 -42.54 2.00
2020-03-31 0.12 47.20 -46.96 2.00
2019-03-31 -49.10 -48.10 -50.10 2.00
DB:3NQ Past Financials Data
Date (Data in JPY Millions) EPS *
2018-12-31 -49.64
2018-09-30 -96.34
2018-06-30 -109.85
2018-03-31 -125.37
2017-12-31 -128.53
2017-09-30 -68.41
2017-06-30 -66.89
2017-03-31 -62.07
2016-12-31 -67.94
2016-09-30 -79.41
2016-06-30 -76.77
2016-03-31 -59.52

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if NanoCarrier will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess NanoCarrier's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
NanoCarrier has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has NanoCarrier performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare NanoCarrier's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • NanoCarrier does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare NanoCarrier's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare NanoCarrier's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
NanoCarrier's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from NanoCarrier Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:3NQ Past Revenue, Cash Flow and Net Income Data
Date (Data in JPY Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 456.00 -2,245.00 -2,581.00 4,979.00
2018-09-30 406.00 -4,276.00 -558.00 4,979.00
2018-06-30 266.00 -4,793.00 -156.00 4,979.00
2018-03-31 259.00 -5,416.00 465.00 4,979.00
2017-12-31 213.00 -5,551.00 3,298.00 2,252.00
2017-09-30 205.00 -2,954.00 1,325.00 2,252.00
2017-06-30 215.00 -2,888.00 1,174.00 2,252.00
2017-03-31 218.00 -2,676.00 528.00 2,252.00
2016-12-31 298.00 -2,920.00 914.00 1,832.00
2016-09-30 313.00 -3,402.00 798.00 1,832.00
2016-06-30 269.00 -3,278.00 587.00 1,832.00
2016-03-31 243.00 -2,537.00 393.00 1,832.00
2015-12-31 405.00 -1,616.00 836.00 1,053.00
2015-09-30 377.00 -962.00 681.00 1,053.00
2015-06-30 631.00 -52.00 502.00 1,053.00
2015-03-31 675.00 -207.00 466.00 1,053.00
2014-12-31 386.00 -443.00 492.00 926.00
2014-09-30 458.00 -827.00 405.00 926.00
2014-06-30 379.00 -1,383.00 451.00 926.00
2014-03-31 472.00 -1,113.00 418.00 926.00
2013-12-31 616.00 -762.00 973.00 237.00
2013-09-30 599.00 -653.00 794.00 237.00
2013-06-30 513.00 -495.00 573.00 237.00
2013-03-31 373.00 -484.00 347.00 237.00
2012-12-31 336.00 -466.00 361.00 203.00
2012-09-30 235.00 -556.00 332.00 203.00
2012-06-30 351.00 -423.00 353.00 203.00

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if NanoCarrier has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if NanoCarrier has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if NanoCarrier improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess NanoCarrier's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
NanoCarrier has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is NanoCarrier's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up NanoCarrier's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • NanoCarrier is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • NanoCarrier's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of NanoCarrier's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.5x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from NanoCarrier Company Filings, last reported 3 months ago.

DB:3NQ Past Debt and Equity Data
Date (Data in JPY Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 4,845.00 2,475.00 5,684.00
2018-09-30 5,688.00 2,475.00 6,208.00
2018-06-30 5,480.00 2,475.00 6,564.00
2018-03-31 4,660.00 2,475.00 6,407.00
2017-12-31 5,428.00 2,475.00 7,135.00
2017-09-30 8,062.00 2,475.00 9,630.00
2017-06-30 8,850.00 2,475.00 10,559.00
2017-03-31 10,066.00 2,475.00 11,769.00
2016-12-31 10,989.00 2,475.00 12,582.00
2016-09-30 10,966.00 2,475.00 12,576.00
2016-06-30 11,688.00 2,475.00 12,906.00
2016-03-31 12,127.00 3,000.00 13,760.00
2015-12-31 13,284.00 3,000.00 14,880.00
2015-09-30 13,624.00 0.00 12,941.00
2015-06-30 14,213.00 0.00 13,619.00
2015-03-31 14,500.00 0.00 13,771.00
2014-12-31 13,688.00 540.00 13,574.00
2014-09-30 13,480.00 540.00 10,364.00
2014-06-30 13,147.00 540.00 10,159.00
2014-03-31 13,595.00 540.00 7,246.00
2013-12-31 14,041.00 540.00 7,833.00
2013-09-30 5,110.00 540.00 5,359.00
2013-06-30 4,422.00 1,040.00 5,124.00
2013-03-31 4,400.00 1,040.00 5,155.00
2012-12-31 3,425.00 1,700.00 4,806.00
2012-09-30 1,639.00 1,700.00 3,119.00
2012-06-30 1,701.00 1,700.00 2,773.00
  • NanoCarrier's level of debt (51.1%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (3.8% vs 51.1% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • NanoCarrier has sufficient cash runway for 1.3 years based on current free cash flow.
  • NanoCarrier has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 32.6% each year.
X
Financial health checks
We assess NanoCarrier's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. NanoCarrier has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is NanoCarrier's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from NanoCarrier dividends. Estimated to be 0.09% next year.
If you bought €2,000 of NanoCarrier shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate NanoCarrier's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate NanoCarrier's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:3NQ Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:3NQ Future Dividends Estimate Data
Date (Data in ¥) Dividend per Share (annual) Avg. No. Analysts
2024-03-31 2.00 1.00
2023-03-31 0.00 1.00
2022-03-31 0.00 1.00
2021-03-31 0.00 1.00
2020-03-31 0.00 1.00
2019-03-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as NanoCarrier has not reported any payouts.
  • Unable to verify if NanoCarrier's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of NanoCarrier's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as NanoCarrier has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of NanoCarrier's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess NanoCarrier's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can NanoCarrier afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. NanoCarrier has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of NanoCarrier's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Ichiro Nakatomi
AGE 68
TENURE AS CEO 22.8 years
CEO Bio

Dr. Ichiro Nakatomi, Ph. D has been the Chief Executive Officer and President at NanoCarrier Co., Ltd. since June 1996. Mr. Nakatomi served as President of TheraTech Japan since October 1993. Mr. Nakatomi served at Hisamitsu Pharmaceutical Co., Ltd. since April 1978. Mr. Nakatomi served as Vice President of Business Development at TheraTech, Inc. since January 1991. He has been a Director of iPS Academia Japan Inc. since August 2008. Mr. Nakatomi has been a Representative Director of NanoCarrier Co., Ltd. since June 1996.

CEO Compensation
  • Insufficient data for Ichiro to compare compensation growth.
  • Insufficient data for Ichiro to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure of the NanoCarrier management team in years:

10.8
Average Tenure
  • The average tenure for the NanoCarrier management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Ichiro Nakatomi

TITLE
Chief Executive Officer
AGE
68
TENURE
22.8 yrs

Tetsuhito Matsuyama

TITLE
Chief Financial Officer
TENURE
4.3 yrs

Hiroyuki Hanada

TITLE
Chief Business Officer and Director
AGE
62
TENURE
10.8 yrs
Board of Directors Tenure

Average tenure and age of the NanoCarrier board of directors in years:

12.6
Average Tenure
68
Average Age
  • The average tenure for the NanoCarrier board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

Ichiro Nakatomi

TITLE
Chief Executive Officer
AGE
68
TENURE
22.8 yrs

Tetsuhito Matsuyama

TITLE
Chief Financial Officer

Hiroyuki Hanada

TITLE
Chief Business Officer and Director
AGE
62
TENURE
10.8 yrs

Teruo Okano

TITLE
External Director
AGE
69
TENURE
22.8 yrs

Akira Ohashi

TITLE
External Director
AGE
75
TENURE
15.8 yrs

Atsushi Matsumura

TITLE
External Director
AGE
56
TENURE
7.1 yrs

Tomoyuki Fujisawa

TITLE
External Director
AGE
52
TENURE
4.8 yrs

Tadashi Morishima

TITLE
External Auditor
AGE
70
TENURE
19.5 yrs

Toshio Furuta

TITLE
External Auditor
AGE
56
TENURE
12.6 yrs

Kanshiro Noguchi

TITLE
Corporate Auditor
AGE
71
TENURE
9.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess NanoCarrier's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. NanoCarrier has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

NanoCarrier Co., Ltd. researches, develops, produces, and sells pharmaceutical products using micellar nanoparticle technology primarily for the treatment of cancer in Japan. Its product pipeline includes NC-6004 Cisplatin micelle for the treatment of pancreatic, head and neck, non-small cell lung, bladder, and biliary track cancers; and VB-111, a non-replicating Adeno 5 vector for the treatment of rGBM/ovarian cancer, etc. The company’s product pipeline also comprise NC-6300 Epirubicin micelle for soft tissue sarcoma; NC-4016 Dach-platinum micelle for solid cancers; and NK105 Paclitaxel micella for the treatment of breast and gastric cancers. NanoCarrier Co., Ltd. was founded in 1996 and is headquartered in Kashiwa, Japan.

Details
Name: NanoCarrier Co., Ltd.
3NQ
Exchange: DB
Founded: 1996
¥168,368,137
49,402,584
Website: http://www.nanocarrier.co.jp
Address: NanoCarrier Co., Ltd.
Chuou 144-15,
226-39 Wakashiba,
Kashiwa,
Chiba, 277-0871,
Japan
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSE 4571 Common Shares The Tokyo Stock Exchange JP JPY 05. Mar 2008
DB 3NQ Common Shares Deutsche Boerse AG DE EUR 05. Mar 2008
Number of employees
Current staff
Staff numbers
51
NanoCarrier employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/21 21:09
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/05
Last earnings filing: 2019/02/13
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.